The protective effect of human platelet lysate in models of neurodegenerative disease: Involvement of the Akt and MEK pathways

Flore Gouel, Bruce Do Van, Ming Li Chou, Aurélie Jonneaux, Caroline Moreau, Régis Bordet, Thierry Pierre Robert Burnouf, Jean Christophe Devedjian, David Devos

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Neurodegenerative diseases have huge economic and societal impacts, and place an immense emotional burden on patients and caregivers. Given that platelets have an essential physiological role in wound healing and tissue repair, human platelet lysates (HPLs) are being developed as a novel, effective biotherapy for neurodegenerative diseases. HPLs constitute abundant, readily accessible sources of physiological mixtures of many growth factors (GFs), with demonstrable effects on neuron survival and thus the development, maintenance, function and plasticity of the vertebrate nervous system. Here, we found that HPLs had marked neuroprotective abilities in cell-based models of Parkinson's disease and amyotrophic lateral sclerosis (the LUHMES and NSC-34 cell lines, respectively). The HPLs protected against specific cell death pathways (apoptosis and ferroptosis) and specific oxidative stress inducers [1-methyl-4-phenylpyridinium (MPP+) and menadione], and always afforded more protection than commonly used recombinant GFs (rGFs). The mechanism of protection of HPLs involved specific signalling pathways: whereas the Akt pathway was activated by HPLs under all conditions, the MEK pathway appeared to be more specifically involved in protection against MPP+ toxicity in LUHMES and, in a lesser extent, in staurosporine toxicity in NSC-34. Our present results suggest that HPLs-based therapies could be used to prevent neuronal loss in neurodegenerative diseases while overcoming the limitations currently associated with use of rGFs.

Original languageEnglish
JournalJournal of Tissue Engineering and Regenerative Medicine
DOIs
Publication statusPublished - 2017

Fingerprint

Neurodegenerative diseases
Mitogen-Activated Protein Kinase Kinases
Platelets
Neurodegenerative Diseases
Blood Platelets
Cell death
Toxicity
Intercellular Signaling Peptides and Proteins
1-Methyl-4-phenylpyridinium
Vitamin K 3
Biological Therapy
Oxidative stress
Staurosporine
Amyotrophic Lateral Sclerosis
Neurology
Wound Healing
Nervous System
Caregivers
Neurons
Plasticity

Keywords

  • Akt
  • Human platelet lysates
  • LUHMES
  • MEK
  • Neuroprotection
  • NSC-34

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biomaterials
  • Biomedical Engineering

Cite this

The protective effect of human platelet lysate in models of neurodegenerative disease : Involvement of the Akt and MEK pathways. / Gouel, Flore; Do Van, Bruce; Chou, Ming Li; Jonneaux, Aurélie; Moreau, Caroline; Bordet, Régis; Burnouf, Thierry Pierre Robert; Devedjian, Jean Christophe; Devos, David.

In: Journal of Tissue Engineering and Regenerative Medicine, 2017.

Research output: Contribution to journalArticle

Gouel, Flore ; Do Van, Bruce ; Chou, Ming Li ; Jonneaux, Aurélie ; Moreau, Caroline ; Bordet, Régis ; Burnouf, Thierry Pierre Robert ; Devedjian, Jean Christophe ; Devos, David. / The protective effect of human platelet lysate in models of neurodegenerative disease : Involvement of the Akt and MEK pathways. In: Journal of Tissue Engineering and Regenerative Medicine. 2017.
@article{2977d0dd61cb466bbbfcf77935d1413f,
title = "The protective effect of human platelet lysate in models of neurodegenerative disease: Involvement of the Akt and MEK pathways",
abstract = "Neurodegenerative diseases have huge economic and societal impacts, and place an immense emotional burden on patients and caregivers. Given that platelets have an essential physiological role in wound healing and tissue repair, human platelet lysates (HPLs) are being developed as a novel, effective biotherapy for neurodegenerative diseases. HPLs constitute abundant, readily accessible sources of physiological mixtures of many growth factors (GFs), with demonstrable effects on neuron survival and thus the development, maintenance, function and plasticity of the vertebrate nervous system. Here, we found that HPLs had marked neuroprotective abilities in cell-based models of Parkinson's disease and amyotrophic lateral sclerosis (the LUHMES and NSC-34 cell lines, respectively). The HPLs protected against specific cell death pathways (apoptosis and ferroptosis) and specific oxidative stress inducers [1-methyl-4-phenylpyridinium (MPP+) and menadione], and always afforded more protection than commonly used recombinant GFs (rGFs). The mechanism of protection of HPLs involved specific signalling pathways: whereas the Akt pathway was activated by HPLs under all conditions, the MEK pathway appeared to be more specifically involved in protection against MPP+ toxicity in LUHMES and, in a lesser extent, in staurosporine toxicity in NSC-34. Our present results suggest that HPLs-based therapies could be used to prevent neuronal loss in neurodegenerative diseases while overcoming the limitations currently associated with use of rGFs.",
keywords = "Akt, Human platelet lysates, LUHMES, MEK, Neuroprotection, NSC-34",
author = "Flore Gouel and {Do Van}, Bruce and Chou, {Ming Li} and Aur{\'e}lie Jonneaux and Caroline Moreau and R{\'e}gis Bordet and Burnouf, {Thierry Pierre Robert} and Devedjian, {Jean Christophe} and David Devos",
year = "2017",
doi = "10.1002/term.2222",
language = "English",
journal = "Journal of Tissue Engineering and Regenerative Medicine",
issn = "1932-6254",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - The protective effect of human platelet lysate in models of neurodegenerative disease

T2 - Involvement of the Akt and MEK pathways

AU - Gouel, Flore

AU - Do Van, Bruce

AU - Chou, Ming Li

AU - Jonneaux, Aurélie

AU - Moreau, Caroline

AU - Bordet, Régis

AU - Burnouf, Thierry Pierre Robert

AU - Devedjian, Jean Christophe

AU - Devos, David

PY - 2017

Y1 - 2017

N2 - Neurodegenerative diseases have huge economic and societal impacts, and place an immense emotional burden on patients and caregivers. Given that platelets have an essential physiological role in wound healing and tissue repair, human platelet lysates (HPLs) are being developed as a novel, effective biotherapy for neurodegenerative diseases. HPLs constitute abundant, readily accessible sources of physiological mixtures of many growth factors (GFs), with demonstrable effects on neuron survival and thus the development, maintenance, function and plasticity of the vertebrate nervous system. Here, we found that HPLs had marked neuroprotective abilities in cell-based models of Parkinson's disease and amyotrophic lateral sclerosis (the LUHMES and NSC-34 cell lines, respectively). The HPLs protected against specific cell death pathways (apoptosis and ferroptosis) and specific oxidative stress inducers [1-methyl-4-phenylpyridinium (MPP+) and menadione], and always afforded more protection than commonly used recombinant GFs (rGFs). The mechanism of protection of HPLs involved specific signalling pathways: whereas the Akt pathway was activated by HPLs under all conditions, the MEK pathway appeared to be more specifically involved in protection against MPP+ toxicity in LUHMES and, in a lesser extent, in staurosporine toxicity in NSC-34. Our present results suggest that HPLs-based therapies could be used to prevent neuronal loss in neurodegenerative diseases while overcoming the limitations currently associated with use of rGFs.

AB - Neurodegenerative diseases have huge economic and societal impacts, and place an immense emotional burden on patients and caregivers. Given that platelets have an essential physiological role in wound healing and tissue repair, human platelet lysates (HPLs) are being developed as a novel, effective biotherapy for neurodegenerative diseases. HPLs constitute abundant, readily accessible sources of physiological mixtures of many growth factors (GFs), with demonstrable effects on neuron survival and thus the development, maintenance, function and plasticity of the vertebrate nervous system. Here, we found that HPLs had marked neuroprotective abilities in cell-based models of Parkinson's disease and amyotrophic lateral sclerosis (the LUHMES and NSC-34 cell lines, respectively). The HPLs protected against specific cell death pathways (apoptosis and ferroptosis) and specific oxidative stress inducers [1-methyl-4-phenylpyridinium (MPP+) and menadione], and always afforded more protection than commonly used recombinant GFs (rGFs). The mechanism of protection of HPLs involved specific signalling pathways: whereas the Akt pathway was activated by HPLs under all conditions, the MEK pathway appeared to be more specifically involved in protection against MPP+ toxicity in LUHMES and, in a lesser extent, in staurosporine toxicity in NSC-34. Our present results suggest that HPLs-based therapies could be used to prevent neuronal loss in neurodegenerative diseases while overcoming the limitations currently associated with use of rGFs.

KW - Akt

KW - Human platelet lysates

KW - LUHMES

KW - MEK

KW - Neuroprotection

KW - NSC-34

UR - http://www.scopus.com/inward/record.url?scp=85006789510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006789510&partnerID=8YFLogxK

U2 - 10.1002/term.2222

DO - 10.1002/term.2222

M3 - Article

C2 - 27943621

AN - SCOPUS:85006789510

JO - Journal of Tissue Engineering and Regenerative Medicine

JF - Journal of Tissue Engineering and Regenerative Medicine

SN - 1932-6254

ER -